Introduction
Multiple sclerosis (MS) is a devastating neurodegenerative disease, characterized by chronic inflammation and demyelination, which is more common in women than men (Sadovnick, 2009) . The increased risk of MS in women is often accompanied by a remission of symptoms when high levels of ovarian hormones are present, such as during pregnancy (Airas et al., 2008; Confavreux et al., 1998) . Experimental autoimmune encephalomyelitis (EAE), the animal model of MS, has been used extensively to investigate the hormonal regulation of immunomodulatory pathways involved. Pretreatment with 17β-estradiol or treatment with ethinyl estradiol decreases inflammatory cytokines and demyelination in the spinal cord of EAE mice (Bebo et al., 2001; Ito et al., 2001; Subramanian et al., 2003) , while 17β-estradiol also increases regulatory T cells (Polanczyk et al., 2004) . Although estrogens may be important contributors, other hormones may be crucial to the immune modulation that occurs. Pretreatment with progesterone decreases disease severity and reduces axonal damage and demyelination (Garay et al., 2007; Garay et al., 2009 ) although results have been mixed (Kim et al., 1999) . There is significant evidence that progesterone can have immunomodulatory and neuroprotective effects in other models (De Leon-Nava et al., 2009; Drew and Chavis, 2000; Gonzalez et al., 2005; Hughes et al., 2008; Otsuki et al., 2001 ). However, effects of progesterone treatment beginning after EAE onset have not been reported. In the present study, the effects of progesterone treatment after EAE disease onset are explored.
Materials and methods

Animals and hormone treatment
Female C57BL/6 mice were obtained from Harlan Laboratories (Houston, TX) and housed at the Portland VA Medical Center in accordance with institutional guidelines. At 7-8 weeks of age, mice were immunized with 200 µg MOG 35-55 peptide (PolyPeptide laboratories; San Diego, CA) and 200 µg complete Freund's adjuvant. Mice received pertussis toxin at the time of immunization (d0; 75 ng) and on d2 (200 ng). Animals were scored daily for disease severity: 0 = normal, 1 = limp tail, 2 = mild hindlimb weakness, 3 = moderate hindlimb weakness, 4 = severe weakness or partial paralysis, 5 = complete hindlimb paralysis, and 6 = moribund.
At the onset of EAE (the first day with a score of 1 or greater), animals were randomly assigned to receive either a subcutaneous progesterone implant (100 mg 60 day release, Innovative Research of America; Sarasota, FL) or placebo treatment. 
